Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2792896 | 1.00 | L3MBTL1 (0.36) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL2797900 | 1.00 | L3MBTL1 (0.36) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL5792460 | 0.93 | MAPK1 (0.33) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL4524592 | 0.93 | MAPK1 (0.33) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL8309292 | 0.93 | MAPK1 (0.33) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL8308908 | 0.93 | MAPK1 (0.33) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL4516595 | 0.93 | MAPK1 (0.33) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL19839514 | 0.87 | L3MBTL1 (0.43) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL13715499 | 0.87 | L3MBTL1 (0.43) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 | |
| SCHEMBL8308654 | 0.87 | MAPK1 (0.33) | L3MBTL1TDP1MAPK1SMN1; SMN2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168197-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168197-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | L3MBTL1 4108/4885TDP1 4251/4885MAPK1 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.